Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Free Research Reports on DRYS, LCC, OREX and ZQK Issued by the Bedford Report

Free Research Reports on DRYS, LCC, OREX and ZQK Issued by the Bedford Report
http://media.marketwire.com/attachments/201211/53317_equitynewscircuit-logo-final.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=971305&ProfileId=051205&sourceType=1

NEW YORK, NY -- (Marketwire) -- 01/07/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

DryShips Inc. (NASDAQ: DRYS) shares soared 25 percent on nearly 30 million shares traded Friday. Shipping stocks were boosted by a swing in the Baltic Dry Index, which posted a gained for the first time since November 28, 2012.

Find out more about DryShips including full access to the free equity report at: www.BedfordReport.com/DRYS

US Airways Group, Inc. (NYSE: LCC) shares spiked 8 percent on double the average daily volume Friday. The airline reported consolidated traffic in December increased 1.8 percent year-over-year.

Find out more about US Airways Group including full access to the free equity report at: www.BedfordReport.com/LCC

Orexigen Therapeutics, Inc. (NASDAQ: OREX) lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. Shares of the company have soared 275 percent in the past year.

Find out more about Orexigen Therapeutics including full access to the free equity report at: www.BedfordReport.com/OREX

Quiksilver, Inc. (NYSE: ZQK) shares surged 12 percent on more than four times the average daily volume Friday. Analysts at Goldman Sachs have upgraded the company's rating to "buy" and increased its 12-month price target to $6.50.

Find out more about Quiksilver including full access to the free equity report at: www.BedfordReport.com/ZQK

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information:

Equity News Circuit
Email Contact